安立生坦治疗肺动脉高压：对临床状况、运动能力和血流动力学的长期影响。 - Suppr

Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.

作者信息

D'Alto Michele, Romeo Emanuele, Argiento Paola, Correra Anna, Sarubbi Berardo, Scognamiglio Giancarlo, Grimaldi Nicola, Pignatiello Maria, Calabrò Raffaele, Russo Maria G

出版信息

Int J Cardiol. 2012 Apr 19;156(2):244-5. doi: 10.1016/j.ijcard.2012.01.054. Epub 2012 Feb 12.

DOI:10.1016/j.ijcard.2012.01.054

PMID:22330004

Abstract

摘要

相似文献

Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.

Int J Cardiol. 2012 Apr 19;156(2):244-5. doi: 10.1016/j.ijcard.2012.01.054. Epub 2012 Feb 12.

Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.

Arthritis Rheum. 2012 Dec;64(12):4072-7. doi: 10.1002/art.34614.

Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.

Z Gastroenterol. 2011 Sep;49(9):1258-62. doi: 10.1055/s-0031-1273393. Epub 2011 Sep 1.

Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.

Am J Cardiol. 2011 May 1;107(9):1381-5. doi: 10.1016/j.amjcard.2010.12.051. Epub 2011 Mar 2.

Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension.

Pulm Pharmacol Ther. 2014 Jun;28(1):87-89. doi: 10.1016/j.pupt.2014.03.002. Epub 2014 Mar 18.

An update on the use of ambrisentan in pulmonary arterial hypertension.

Ther Adv Respir Dis. 2012 Dec;6(6):331-43. doi: 10.1177/1753465812458014. Epub 2012 Aug 29.

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

Am J Cardiol. 2011 Jul 15;108(2):302-7. doi: 10.1016/j.amjcard.2011.03.037. Epub 2011 May 3.

Ambrisentan and its role in the management of pulmonary arterial hypertension.

Drugs Today (Barc). 2008 Dec;44(12):875-85. doi: 10.1358/dot.2008.44.12.1310761.

Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.

Hypertens Res. 2014 Jun;37(6):507-12. doi: 10.1038/hr.2014.28. Epub 2014 Mar 20.

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.

Expert Opin Pharmacother. 2009 Aug;10(11):1847-58. doi: 10.1517/14656560903061275.

引用本文的文献

Contribution of pressure and flow changes to resistance reduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients.

ERJ Open Res. 2024 Jan 22;10(1). doi: 10.1183/23120541.00706-2023. eCollection 2024 Jan.

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension.

Front Pharmacol. 2020 Apr 3;11:400. doi: 10.3389/fphar.2020.00400. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献